{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:10:00Z","timestamp":1753881000974,"version":"3.41.2"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,2,15]]},"abstract":"<jats:p>\n            This phase 2 study investigated long-term safety and efficacy of rilpivirine (RPV [Edurant]) plus two investigator-selected nucleos(t)ide reverse transcriptase inhibitors (NRTIs) in HIV-1-infected antiviral therapy-naive adolescents. Participants (\u226512 to &lt;18\u2009years of age) were treated with RPV at 25\u2009mg once daily (q.d.) plus\u20092 NRTIs for participants who entered the treatment extension period for up to 240\u2009weeks, with visits every 3\u2009months. Long-term safety (analysis of adverse events [AEs] and laboratory results), efficacy (virologic response and outcome for patients with viral loads of &lt;50 and &lt;400 by time to loss of virologic response [TLOVR] and FDA Snapshot methods, as well as CD4\n            <jats:sup>+<\/jats:sup>\n            cell count), and adherence (by pill count) for up to 240\u2009weeks are presented.\n          <\/jats:p>","DOI":"10.1128\/aac.00916-21","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T18:17:16Z","timestamp":1638814636000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3229-7182","authenticated-orcid":true,"given":"Johan","family":"Lombaard","sequence":"first","affiliation":[{"name":"Josha Research, Bloemfontein, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Ssali","sequence":"additional","affiliation":[{"name":"Joint Clinical Research Centre, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puthanakit","family":"Thanyawee","sequence":"additional","affiliation":[{"name":"Thai Red Cross AIDS Research Centre, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Fourie","sequence":"additional","affiliation":[{"name":"Jan Fourie Medical Practice, Dundee, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Vanveggel","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Linthicum","sequence":"additional","affiliation":[{"name":"Janssen Vaccines AG, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Van Eygen","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodica","family":"Van Solingen-Ristea","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000649"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31829e6b9f"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540120020018161"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.45.239.13"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.157.3.249"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31824d006e"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835cee6e"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835e1554"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001275"},{"key":"e_1_3_3_11_2","unstructured":"Lombaard J Bunupuradah T Flynn P Ramapuram J Ssali F Vanveggel S Williams P Yarnall W Stevens M. 2014. Safety and efficacy of a rilpivirine-based regimen in HIV-infected treatment-naive adolescents: week 24 primary analysis of the PAINT phase II trial abstr O_05. 6th Int Workshop HIV Pediatr. http:\/\/regist2.virology-education.com\/2014\/6thHIVped\/10_Lombaard.pdf."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000994"},{"key":"e_1_3_3_13_2","unstructured":"McHugh G Simms V Dauya E Bandason T Mujuru H Munyati S Weiss H Rehman AM Odland J Ferrand. 2018. Targeting the third \u201c90\u201d: are children and adolescents slipping through the net? 22nd Int AIDS Conf Amsterdam the Netherlands 23 to 27 July 2018. http:\/\/programme.aids2018.org\/Abstract\/Abstract\/5471."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31822d7564"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3372-6"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-0925"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piy139"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318125720a"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000038"},{"key":"e_1_3_3_20_2","unstructured":"World Health Organization. 2018. The 2018 Optimal Formulary and Limited Use List for Pediatric ARVs. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/273153\/WHO-CDS-HIV-18.15-eng.pdf?ua=1."},{"key":"e_1_3_3_21_2","unstructured":"World Health Organization. 2018. AIDS Free Framework to accelerate paediatric and adolescent HIV treatment. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/273150\/WHO-CDS-HIV-18.20-eng.pdf."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.44.235.291"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00986-09"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31823df4da"},{"key":"e_1_3_3_25_2","first-page":"125","article-title":"Update of the drug resistance mutations in HIV-1: Fall 2006","volume":"14","author":"Johnson VA","year":"2006","unstructured":"Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. 2006. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 14:125\u2013130.","journal-title":"Top HIV Med"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2358"},{"key":"e_1_3_3_27_2","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). November 2015. Guidance for Industry. Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment. https:\/\/www.fda.gov\/media\/86284\/download. Accessed 13 March 2020."},{"key":"e_1_3_3_28_2","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). October 2002. Guidance for Industry. Antiretroviral drugs using plasma HIV RNA measurements\u2014clinical considerations for accelerated and traditional approval. http:\/\/bibliobase.sermais.pt:8008\/BiblioNET\/Upload\/PDF3\/002486.pdf. Accessed March 2019."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001817"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00916-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00916-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:28:27Z","timestamp":1645486107000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00916-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,15]]}},"alternative-id":["10.1128\/aac.00916-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.00916-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2022,2,15]]},"assertion":[{"value":"2021-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00916-21"}}